ClinicalTrials.Veeva

Menu

A Randomized-Controlled Trial to Increase the Uptake of LARCs in Cameroon (HGOPY)

W

World Bank

Status

Completed

Conditions

Contraception
Contraception Behavior
Contraceptive Usage
Contraceptive Method Switching

Treatments

Behavioral: Sequential vs. simultaneous recommendations
Behavioral: Price discounts for SARCs
Behavioral: Price discounts for LARCs

Study type

Interventional

Funder types

Other

Identifiers

NCT03733678
LARCs-2018

Details and patient eligibility

About

Cameroon exhibits a high and non-decreasing level of maternal mortality (roughly 600 per 100,000 live births), partially related to its relatively high total fertility rate (roughly 4.6). Survey evidence furthermore suggests that a significant fraction of these pregnancies is unwanted or considered mistimed by the mother, especially among females aged 15-19. Despite this, the rate of utilization of family planning (FP) is low: e.g. only 48% of sexually active unmarried women use any form of (modern) contraception, or MC, and even then, it is primarily condoms. The use of LARCs (long-acting reversible contraceptives, i.e. the IUD and implant) is less than 1% according to the most recent Demographic Health Survey.

The study investigators propose to use an integrated behavioral science approach to increase the take-up of both SARCs (short-acting reversible contraceptives, i.e. the pill and injectable) and especially LARCs among reproductive-age females in Cameroon, including adolescents who may be unmarried and/or nulliparous. In addition to decreasing maternal mortality and undesired pregnancies, indirect effects for the community will include: increased welfare from reduced side effects that arise due to current one-size-fits-all FP counseling; healthier children due to improved birth spacing; and increased human capital formation both for children and for young (often school-aged) potential mothers.

The study investigators propose to conduct the study at HGOPY for a duration of 12 months. The study investigators will provide tablets to each of five nurses that conduct FP counseling to participants at the hospital. The tablets contain a counseling "app" (or decision-support tool or a job-aid) that was jointly developed by professionals from HGOPY, the World Bank, and the Ministry of Health. The study investigators propose an individually-randomized experiment, where the participants will be offered randomly varying discounts for the modern contraceptive methods they wish to adopt. The study investigators also propose to experiment with certain aspects of the "app" to improve its effectiveness - both for the participant and for the nurse. More details on the experimental design are provided below.

Enrollment

2,500 patients

Sex

Female

Ages

10 to 49 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Female
  • Ages 10-49
  • Presenting at HGOPY seeking FP counseling/services
  • HGOPY clients referred to the family planning unit for consultation

Exclusion criteria

* No exclusion criteria

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

Single Blind

2,500 participants in 20 patient groups

Free SARC, Free LARC, Recommendation
Experimental group
Description:
Free SARC, Free LARC, Sequential recommendation
Treatment:
Behavioral: Price discounts for LARCs
Behavioral: Price discounts for SARCs
Free SARC, LARC=500, Recommendation
Experimental group
Description:
Free SARC, LARC=500 CFA, Sequential recommendation
Treatment:
Behavioral: Price discounts for LARCs
Behavioral: Price discounts for SARCs
Free SARC, LARC=1000, Recommendation
Experimental group
Description:
Free SARC, LARC=1000 CFA, Sequential recommendation
Treatment:
Behavioral: Price discounts for LARCs
Behavioral: Price discounts for SARCs
Free SARC, LARC=2140, Recommendation
Experimental group
Description:
Free SARC, LARC=2140 CFA, Sequential recommendation
Treatment:
Behavioral: Price discounts for LARCs
Behavioral: Price discounts for SARCs
Free SARC, LARC=5000, Recommendation
Experimental group
Description:
Free SARC, LARC=5000 CFA, Sequential recommendation
Treatment:
Behavioral: Price discounts for SARCs
Regular SARC, Free LARC, Recommendation
Experimental group
Description:
Regular price SARC, Free LARC, Sequential recommendation
Treatment:
Behavioral: Price discounts for LARCs
Regular SARC, LARC=500, Recommendation
Experimental group
Description:
Regular price SARC, LARC=500 CFA, Sequential recommendation
Treatment:
Behavioral: Price discounts for LARCs
Regular SARC, LARC=1000, Recommendation
Experimental group
Description:
Regular price SARC, LARC=1000 CFA, Sequential recommendation
Treatment:
Behavioral: Price discounts for LARCs
Regular SARC, LARC=2140, Recommendation
Experimental group
Description:
Regular price SARC, LARC=2140 CFA, Sequential recommendation
Treatment:
Behavioral: Price discounts for LARCs
Regular SARC, LARC=5000, Recommendation
No Intervention group
Description:
Regular price SARC, LARC=5000 CFA, Sequential recommendation
Free SARC, Free LARC, No Recommendation
Experimental group
Description:
Free SARC, Free LARC, Simultaneous recommendation
Treatment:
Behavioral: Price discounts for LARCs
Behavioral: Sequential vs. simultaneous recommendations
Behavioral: Price discounts for SARCs
Free SARC, LARC=500, No Recommendation
Experimental group
Description:
Free SARC, LARC=500 CFA, Simultaneous recommendation
Treatment:
Behavioral: Price discounts for LARCs
Behavioral: Sequential vs. simultaneous recommendations
Behavioral: Price discounts for SARCs
Free SARC, LARC=1000, No Recommendation
Experimental group
Description:
Free SARC, LARC=1000 CFA, Simultaneous recommendation
Treatment:
Behavioral: Price discounts for LARCs
Behavioral: Sequential vs. simultaneous recommendations
Behavioral: Price discounts for SARCs
Free SARC, LARC=2140, No Recommendation
Experimental group
Description:
Free SARC, LARC=2140 CFA, Simultaneous recommendation
Treatment:
Behavioral: Price discounts for LARCs
Behavioral: Sequential vs. simultaneous recommendations
Behavioral: Price discounts for SARCs
Free SARC, LARC=5000, No Recommendation
Experimental group
Description:
Free SARC, LARC=5000 CFA, Simultaneous recommendation
Treatment:
Behavioral: Sequential vs. simultaneous recommendations
Behavioral: Price discounts for SARCs
Regular SARC, Free LARC, No Recommendation
Experimental group
Description:
Regular Price SARC, Free LARC, Simultaneous recommendation
Treatment:
Behavioral: Price discounts for LARCs
Behavioral: Sequential vs. simultaneous recommendations
Regular SARC, LARC=500, No Recommendation
Experimental group
Description:
Regular Price SARC, LARC=500 CFA, Simultaneous recommendation
Treatment:
Behavioral: Price discounts for LARCs
Behavioral: Sequential vs. simultaneous recommendations
Regular SARC, LARC=1000, No Recommendation
Experimental group
Description:
Regular Price SARC, LARC=1000 CFA, Simultaneous recommendation
Treatment:
Behavioral: Price discounts for LARCs
Behavioral: Sequential vs. simultaneous recommendations
Regular SARC, LARC=2140, No Recommendation
Experimental group
Description:
Regular Price SARC, LARC=2140 CFA, Simultaneous recommendation
Treatment:
Behavioral: Price discounts for LARCs
Behavioral: Sequential vs. simultaneous recommendations
Regular SARC, LARC=5000, No Recommendation
Experimental group
Description:
Regular Price SARC, LARC=5000 CFA, Simultaneous recommendation
Treatment:
Behavioral: Sequential vs. simultaneous recommendations

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems